Sei Investments Co. boosted its position in Illumina, Inc. (NASDAQ:ILMN) by 20.0% during the fourth quarter, Holdings Channel reports. The fund owned 252,974 shares of the life sciences company’s stock after buying an additional 42,132 shares during the quarter. Sei Investments Co.’s holdings in Illumina were worth $55,272,000 at the end of the most recent reporting period.

A number of other institutional investors also recently modified their holdings of the business. Advisory Services Network LLC boosted its position in Illumina by 13.0% in the second quarter. Advisory Services Network LLC now owns 772 shares of the life sciences company’s stock valued at $134,000 after buying an additional 89 shares in the last quarter. Raymond James Financial Services Advisors Inc. boosted its position in Illumina by 2.1% in the second quarter. Raymond James Financial Services Advisors Inc. now owns 5,698 shares of the life sciences company’s stock valued at $989,000 after buying an additional 116 shares in the last quarter. Hemenway Trust Co LLC boosted its position in Illumina by 0.6% in the fourth quarter. Hemenway Trust Co LLC now owns 37,895 shares of the life sciences company’s stock valued at $8,280,000 after buying an additional 227 shares in the last quarter. Daiwa Securities Group Inc. boosted its position in Illumina by 4.3% in the fourth quarter. Daiwa Securities Group Inc. now owns 5,543 shares of the life sciences company’s stock valued at $1,211,000 after buying an additional 229 shares in the last quarter. Finally, Private Asset Management Inc. boosted its position in Illumina by 2.2% in the fourth quarter. Private Asset Management Inc. now owns 11,072 shares of the life sciences company’s stock valued at $2,419,000 after buying an additional 240 shares in the last quarter. Hedge funds and other institutional investors own 92.04% of the company’s stock.

In other Illumina news, Director Jay T. Flatley sold 20,000 shares of Illumina stock in a transaction on Tuesday, November 21st. The shares were sold at an average price of $211.35, for a total value of $4,227,000.00. Following the completion of the sale, the director now directly owns 531,717 shares of the company’s stock, valued at $112,378,387.95. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, Director Robert S. Epstein sold 1,250 shares of Illumina stock in a transaction on Monday, January 29th. The shares were sold at an average price of $244.18, for a total transaction of $305,225.00. Following the completion of the sale, the director now directly owns 8,588 shares of the company’s stock, valued at $2,097,017.84. The disclosure for this sale can be found here. In the last 90 days, insiders sold 114,440 shares of company stock worth $25,318,904. 0.89% of the stock is owned by company insiders.

Illumina, Inc. (NASDAQ ILMN) opened at $220.44 on Wednesday. The stock has a market cap of $32,270.38, a price-to-earnings ratio of 44.44, a P/E/G ratio of 2.92 and a beta of 0.92. The company has a quick ratio of 3.55, a current ratio of 3.99 and a debt-to-equity ratio of 0.42. Illumina, Inc. has a fifty-two week low of $158.02 and a fifty-two week high of $248.97.

Illumina (NASDAQ:ILMN) last released its earnings results on Tuesday, January 30th. The life sciences company reported $1.44 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.22 by $0.22. The business had revenue of $778.00 million for the quarter, compared to analyst estimates of $752.04 million. Illumina had a net margin of 26.56% and a return on equity of 21.52%. Illumina’s revenue for the quarter was up 25.7% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.85 earnings per share. equities analysts expect that Illumina, Inc. will post 4.59 EPS for the current year.

A number of brokerages have recently commented on ILMN. Canaccord Genuity reiterated a “buy” rating and set a $265.00 price target (up previously from $255.00) on shares of Illumina in a report on Wednesday, January 31st. BidaskClub lowered shares of Illumina from a “buy” rating to a “hold” rating in a report on Saturday, February 3rd. Evercore ISI began coverage on shares of Illumina in a report on Wednesday, January 3rd. They set an “outperform” rating and a $250.00 price target on the stock. Barclays lifted their price target on shares of Illumina from $200.00 to $215.00 and gave the stock an “equal weight” rating in a report on Wednesday, January 31st. Finally, First Analysis upgraded shares of Illumina from an “equal weight” rating to an “overweight” rating and set a $277.00 price target on the stock in a report on Wednesday, January 31st. One analyst has rated the stock with a sell rating, eight have given a hold rating and fourteen have issued a buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average target price of $241.39.

COPYRIGHT VIOLATION NOTICE: “Illumina, Inc. (ILMN) Position Lifted by Sei Investments Co.” was published by TheOlympiaReport and is the property of of TheOlympiaReport. If you are reading this story on another site, it was stolen and republished in violation of United States and international copyright and trademark legislation. The legal version of this story can be viewed at https://theolympiareport.com/2018/02/14/illumina-inc-ilmn-position-lifted-by-sei-investments-co.html.

Illumina Company Profile

Illumina, Inc (Illumina) is a provider of sequencing- and array-based solutions for genetic analysis. The Company operates through two segments: Core Illumina and the consolidated variable interest entities (VIEs), which include the activities of GRAIL, Inc (GRAIL) and Helix Holdings I, LLC (Helix). Core Illumina consists of its core operations.

Want to see what other hedge funds are holding ILMN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Illumina, Inc. (NASDAQ:ILMN).

Institutional Ownership by Quarter for Illumina (NASDAQ:ILMN)

Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.